We are live on ! Find out more

3,269 hedge funds and large institutions have $198B invested in Pfizer in 2022 Q4 according to their latest regulatory filings, with 343 funds opening new positions, 1,270 increasing their positions, 1,341 reducing their positions, and 102 closing their positions.

New
Increased
Maintained
Reduced
Closed

236% more first-time investments, than exits

New positions opened: 343 | Existing positions closed: 102

24% more funds holding in top 10

Funds holding in top 10: 156193 (+37)

17% more capital invested

Capital invested by funds: $170B → $198B (+$28.1B)

11% more call options, than puts

Call options by funds: $3.04B | Put options by funds: $2.75B

6% more funds holding

Funds holding: 3,0893,269 (+180)

0.21% less ownership

Funds ownership: 69.16%68.94% (-0.21%)

5% less repeat investments, than reductions

Existing positions increased: 1,270 | Existing positions reduced: 1,341

Holders
3,269
Holders Change
+180
Holders Change %
+5.83%
% of All Funds
52.4%
Holding in Top 10
193
Holding in Top 10 Change
+37
Holding in Top 10 Change %
+23.72%
% of All Funds
3.09%
New
343
Increased
1,270
Reduced
1,341
Closed
102
Calls
$3.04B
Puts
$2.75B
Net Calls
+$292M
Net Calls Change
-$363M

PFE Hedge Fund Activity: Q4 2022 in Review

3,269 of the 6,238 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q4 2022, worth a combined $198B — up 17% from $170B a quarter earlier.

Buyers outnumbered sellers: 343 funds opened new PFE positions and 102 closed out — a net gain of 241 holders — while 1,270 added to existing stakes and 1,341 trimmed.

The largest buyer was BlackRock, adding an estimated $492M. The largest seller was Wellington Management Group, cutting an estimated $553M.

  • 3,269 institutional investors held Pfizer (PFE) as of Q4 2022, up from 3,089 in Q3 2022.
  • Funds reported $198B of Pfizer stock for Q4 2022, up 17% quarter-over-quarter.
  • 343 funds opened new Pfizer positions in Q4 2022 and 102 closed out, a net change of +241 holders.
  • The largest Pfizer buyer in Q4 2022 was BlackRock, an estimated $492M added.
  • The largest Pfizer seller in Q4 2022 was Wellington Management Group, an estimated $553M sold.

Based on aggregated 13F filings for Q4 2022.